Live Chart

O 744.45

H 744.45

L 744.45

VOL 120

Syngene International Performance

Days Range

Low: ₹729.05
High: ₹747.35
Previous Close ₹744.50
Open ₹744.45
Volume 3,65,797
Day’s Range ₹729.05 - ₹747.35
52W Range ₹563.15 - ₹860.25
Market Cap ₹29,879 Cr

Fundamentals of Syngene International

ROCE (TTM) 13.84%
P/E Ratio (TTM) 59.75
P/B Ratio 7.68
Industry P/E 36.61
Debt to Equity 0.21
ROE 12.81%
EPS (TTM) 12.66
Dividend Yield 0.17%
Book Value 97
Face Value 10

Financials of Syngene International

Mar 2023Jun 2023Sep 2023Dec 2023
Net Sales994.4808.1910.1853.5
Expenses775.9698.3760.6730.1
Profit before tax230.9122.9150.7138.2
Operating Profit178.793.4116.5111.5
Net Profit178.793.4116.5111.5
EPS in Rs4.362.333.082.87

About Syngene International

Syngene International Ltd is a listed subsidiary of Biocon. It is a contract research, development and manufacturing organisation (CRDMO) which provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods and agrochemical companies. The company was established in 1993 as  Syngene International Private Limited and initiated operations as a Custom Research Organisation (CRO) with services in chemistry and biology in 1994.

In 2002, 99.9% of the company’s equity shares were transferred to Biocon as Kiran Mazumdar Shaw, a promoter of Biocon, promoted it. As a result, the company became a subsidiary of Biocon. In 2007, the company signed the first long-term contract with Bristol-Myers Squibb to set up its first dedicated R&D centre.

The company continued its growth trajectory and entered a collaboration with Endo Pharmaceuticals to develop novel biological therapeutic molecules against cancer in 2011. It crossed an annual turnover of over ₹5,000 million in 2013. The company’s erstwhile subsidiary, Clinigene International Limited (CIL), was amalgamated into the company in 2015. During the same year, the company was listed on BSE and NSE after an IPO. The company received the Golden Peacock Award for Risk Management in 2023.

Business Segments

  • Discovery Services:  Under this segment, the company is responsible for conducting early-stage research, from identifying biological targets relevant to disease in patient populations to delivering drug candidates for further development.
  • Development Services: The development services division takes drug candidates and provides various services, from pre-clinical to clinical trials, including drug substance, drug product development, and associated services.
  • Manufacturing Services: The company offers commercial-scale manufacturing of small molecules from its cGMP-compliant API manufacturing campus.
  • Dedicated R&D Centers: Under this segment, Syngene provides R&D services. The company’s  R&D Centers are multi-disciplinary teams based in dedicated facilities focusing on biopharmaceutical research for clients including BMS, Amgen and Baxter.

Subsidiary

As of March 2023, the company has 3 subsidiaries listed below:

  • Syngene USA Inc. This wholly-owned subsidiary was incorporated in FY 2018 to support Syngene’s firm foothold in the US market and allow easy access to its clients based in that region.
  • Syngene Scientific Solutions Limited (SSSL): This subsidiary was incorporated in 2022 and is engaged in contract research and clinical research services.
  • Syngene Manufacturing Solutions Limited (SMSL): This subsidiary was incorporated in  2022 to manufacture pharmaceutical, biopharmaceutical and biological products of any kind.

Key Personnel

Jonathan Hunt, Managing Director and Chief Executive Officer

Jonathan holds is the current MD and CEO of the company. His responsibilities revolve around leading the company’s business and driving its investments in developing and strengthening its capabilities and capacities.  He holds a BA (Business Studies & Economics) degree from the University of Sheffield, UK, and has done his MBA from Durham University, United Kingdom. He held leadership positions at AstraZeneca for over a decade before joining Syngene.

Corporate Action

In 2019, the company issued bonus shares in the ratio of 1:1 on a record date of June 11, 2019.

Parent Organisation Indian Private
Founded 1993
Managing Director Kiran Mazumdar Shaw
NSE Symbol SYNGENE

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Ajanta Pharma Ltd ₹26,769.25

2117

8.85 (-0.42%)

2100 - 2152.8
Lupin Ltd ₹73,433.93

1601.85

13.10 (-0.81%)

1580 - 1622.85
Gland Pharma Ltd ₹30,641.97

1831

30.10 (-1.62%)

1811.85 - 1874
Alkem Laboratories Ltd ₹64,799.45

5012

409.15 (-7.55%)

4659 - 5413.8
Glaxosmithkline Pharmaceuticals Ltd ₹36,744.17

2159.95

10.85 (-0.50%)

2154 - 2188

What's Trending

FAQs

What is the Share price of Syngene International (SYNGENE)?

Syngene International (SYNGENE) share price as of February 26, 2024, on NSE is Rs 731.00 (NSE) and Rs 728.30 (BSE) on BSE.

Can I buy Syngene International (SYNGENE) shares?

Yes, You can buy Syngene International (SYNGENE) shares by opening a Demat account with Angel One.

How do I buy Syngene International (SYNGENE) from Angel One?

Syngene International (SYNGENE) share can be brought through the following modes:
  1. Direct investment: You can buy Syngene International (SYNGENE) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Syngene International (SYNGENE) shares.

Is Syngene International a Debt free Company?

No, Syngene International is not a debt free company.

What is the main business of Syngene International?

The main business of Syngene International is to research, develop, and provide scientific molecules and solutions across varied industries, such as pharmaceuticals, animal health, biotechnology, consumer goods, nutrition, and specialty chemical companies.

Who are the promoters of Syngene International?

Some of the main promoters of Syngene International are Biocon Limited, Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha), Kiran Mazumdar Shaw, Biocon Research Limited, Ravi Rasendra Mazumdar, and Dev Mazumdar.

What are the Subsidiaries that comes under Syngene International?

The only wholly-owned subsidiary that comes under Syngene International is Syngene USA Inc.